Loncar Cancer Immunotherapy ETF
Loncar Cancer Immunotherapy TR USD
NAV as of
4 Week: 11.72 - 13.45
52 Week: 11.72 - 19.28
Latest Closing Price
Premium / Discount
The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Main Fund Characteristics
|Period||Performance Returns(%)||Volatility(%)||Risk Adjusted Performance|
Annual Performance Return
|Ex Date||Payment Date||Dividend Payout per unit|
Total Number of Holdings: 32
Number of Bond Holdings: 0
Number of Equity Holdings: 30
Total Market Value: 17,057,297
Top 10 Holdings
|% Portfolio Weight||Shares Owned||Shares Changed||Market Value|
|2||Regeneron Pharmaceuticals Inc||4.5287||963||0||772,480|
|Size||% of portfolio|
Equity Style Box Breakdown
*Forward-looking based on historical data.
Number of Bond Holdings
|Average Effective Duration||0|
|Average Effective Maturity (Years)*||0|
|Average Credit Quality||0|
|Average Weighted Coupon*||0|
|Average Weighted Price*||0|
Bond Style Box Breakdown
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.